PMID- 18046448
OWN - NLM
STAT- MEDLINE
DCOM- 20080326
LR  - 20130304
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 22
IP  - 2
DP  - 2008 Feb
TI  - NK cell receptors and their ligands in leukemia.
PG  - 249-57
AB  - Human natural killer (NK) cells are built to kill abnormal cells but to preserve 
      autologous normal cells. To accomplish this task, they are equipped with a large 
      number of inhibiting and activating receptors. Ligation with corresponding 
      ligands will determine whether the NK cell becomes activated to destroy the 
      abnormal cell. This review will focus on the abnormalities of NK cell receptors 
      and their putative ligands found in patients with leukemia, which can lead to an 
      inadequate function of NK cells allowing these malignant cells to escape from NK 
      cell destruction. In recent years it has become clear that NK cells in the 
      haploidentical hematopoietic stem cell transplantation (HSCT) setting are very 
      effective in eliminating residual acute myeloid, but not acute lymphoid, leukemic 
      cells. In this regard, we also reviewed published studies of retrospective 
      cohorts of HSCT investigating the potential beneficial effect of killer-cell 
      immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) ligands on 
      NK alloreactivity. Manipulating NK cell inhibition or activation could lead to 
      new forms of immunotherapy, ultimately leading to the elimination of resistant 
      leukemic cells.
FAU - Verheyden, S
AU  - Verheyden S
AD  - Department of Hematology, HLA and Molecular Hematology Laboratory, Universitair 
      Ziekenhuis Brussel, Brussels, Belgium.
FAU - Demanet, C
AU  - Demanet C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20071129
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Ligands)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, KIR)
SB  - IM
CIN - Leukemia. 2008 Nov;22(11):2129-30; discussion 2130-1. PMID: 18463675
MH  - Graft vs Leukemia Effect
MH  - Hematopoietic Stem Cell Transplantation/methods
MH  - Histocompatibility Antigens Class I
MH  - Humans
MH  - Immunotherapy/methods
MH  - Killer Cells, Natural/*immunology
MH  - Leukemia/immunology/*therapy
MH  - Ligands
MH  - Receptors, Immunologic/*physiology
MH  - Receptors, KIR
RF  - 83
EDAT- 2007/11/30 09:00
MHDA- 2008/03/28 09:00
CRDT- 2007/11/30 09:00
PHST- 2007/11/30 09:00 [pubmed]
PHST- 2008/03/28 09:00 [medline]
PHST- 2007/11/30 09:00 [entrez]
AID - 2405040 [pii]
AID - 10.1038/sj.leu.2405040 [doi]
PST - ppublish
SO  - Leukemia. 2008 Feb;22(2):249-57. doi: 10.1038/sj.leu.2405040. Epub 2007 Nov 29.